<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328845</url>
  </required_header>
  <id_info>
    <org_study_id>FIM-EOX-2016-01</org_study_id>
    <nct_id>NCT03328845</nct_id>
  </id_info>
  <brief_title>Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)</brief_title>
  <acronym>INEOX</acronym>
  <official_title>Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates in a group of people with DM 1 the influence in parameters of oxidative
      stress of the treatments with the different current analogs of insulin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate by a randomized study in a group of people with DM 1 the influence in parameters
      of oxidative stress of the treatments with the different current analogs of

      Insulin by analyzing:

        1. - The circulating levels of oxidative stress markers: A) Anti oxidation: Total
           antioxidant capacity (CAT), B) Oxidation: 8-iso-prostaglandin F2 alpha (8-iso-PGF2α),
           acid reactive substances Thiobarbituric (TBARS) and LDL-oxidized.

        2. - The relationship between glycemic control variables (HbA1c and mean glycemia) and
           variability (Standard deviation (SD), coefficient of variation (CV), and MAGE (mean
           amplitude of Glycemic excursions) and oxidative stress parameters analyzed.

      Goal 2:

      Study the activation of cellular pathways associated with processes and oxidation states, by
      means of a Array of expression of up to 50 genes encoding oxidative stress response genes as
      CPT1a (Carnitine Palmitoyl Transferase 1a, mitochondrial oxidizing b limiting enzyme), TAS
      (Fatty acyl synthetase), acetyl-coA carboxylase, Acadm (medium chain acyl dehydrogenase),
      Acadl (long chain acyl dehydrogenase), Acadvl (long chain acyl coA dehydrogenase), SOD1,
      Hmox1 and Glutamine-Cysteine ligase (Gclc).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress markers with the new slow insulin analogues</measure>
    <time_frame>6 month</time_frame>
    <description>To evaluate the impact on the circulating levels of oxidative stress markers of the different treatments using the new slow insulin analogues. 1a) Anti oxidation: Total antioxidant capacity (CAT), and 1b) Oxidation: 8-iso-prostaglandin F2 alpha (8-iso-PGF2α), thiobarbituric acid reactive substances (TBARS) and LDL-oxidized</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 month</time_frame>
    <description>Glycemic control: glycosylated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose</measure>
    <time_frame>6 month</time_frame>
    <description>Glycemic control: mean blood glucose (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation</measure>
    <time_frame>6 month</time_frame>
    <description>Glycemic variability :standard deviation [SD]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mild hypoglycemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of mild hypoglycaemia in two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of severe hypoglycemia in the last 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperglycemia</measure>
    <time_frame>6 month</time_frame>
    <description>Number of hyperglycemia&gt; 250 mg / dl in two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodes of ketosis</measure>
    <time_frame>6 month</time_frame>
    <description>Episodes of ketosis in the last 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number os hospital admissions</measure>
    <time_frame>6 month</time_frame>
    <description>Number of hospital admissions for acute diabetes decompensation in the last 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire in diabetes (DQOL)</measure>
    <time_frame>6 month</time_frame>
    <description>34 items on the quality of life of people with type 1 diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale of adherence to treatment in patients with diabetes type 1 (DM1)</measure>
    <time_frame>6 month</time_frame>
    <description>15 items related to adherence to patient treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes distress scale. DDS</measure>
    <time_frame>6 month</time_frame>
    <description>17 items on the problems and stress that people with type 1 diabetes suffer (Polonski y col, 2005)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemia: Questionnaire FH-15</measure>
    <time_frame>6 month</time_frame>
    <description>15 items related to the fear of hypoglycemia in patients with type 1 diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes treatment satisfaction questionnaire (DTSQ).</measure>
    <time_frame>6 month</time_frame>
    <description>8 items concerning the satisfaction of the treatment</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Tresiba &amp; NovoRapid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Tresiba insulin and NovoRapid insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toujeo SoloStar &amp; NovoRapid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Toujeo SoloStar insulin and NovoRapid insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tresiba &amp; Humalog Kwikpen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Tresiba insulin and Humalog kwikpen insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toujeo SoloStar &amp; Humalog Kwikpen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tresiba &amp; Apidra</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Tresiba insulin and Apidra insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toujeo SoloStar &amp; Apidra</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients treated with Toujeo SoloStar insulin and Apidra insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toujeo SoloStar</intervention_name>
    <arm_group_label>Toujeo SoloStar &amp; NovoRapid</arm_group_label>
    <arm_group_label>Toujeo SoloStar &amp; Humalog Kwikpen</arm_group_label>
    <arm_group_label>Toujeo SoloStar &amp; Apidra</arm_group_label>
    <other_name>Glargina U300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tresiba</intervention_name>
    <arm_group_label>Tresiba &amp; NovoRapid</arm_group_label>
    <arm_group_label>Tresiba &amp; Humalog Kwikpen</arm_group_label>
    <arm_group_label>Tresiba &amp; Apidra</arm_group_label>
    <other_name>Degludec insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog Kwikpen</intervention_name>
    <arm_group_label>Tresiba &amp; Humalog Kwikpen</arm_group_label>
    <arm_group_label>Toujeo SoloStar &amp; Humalog Kwikpen</arm_group_label>
    <other_name>Lispro insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NovoRapid</intervention_name>
    <arm_group_label>Tresiba &amp; NovoRapid</arm_group_label>
    <arm_group_label>Toujeo SoloStar &amp; NovoRapid</arm_group_label>
    <other_name>Aspart insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apidra</intervention_name>
    <arm_group_label>Tresiba &amp; Apidra</arm_group_label>
    <arm_group_label>Toujeo SoloStar &amp; Apidra</arm_group_label>
    <other_name>Glulisine insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 years and 65 years (inclusive).

          -  DM1 of more than two years of evolution with habitual follow-up in the Diabetes Unit
             of the University Regional Hospital of Malaga.

          -  HbA1c ≤ 10%

          -  Intensive treatment with basal MDI - Bowl for more than 12 months prior to the start
             of study.

          -  Gives informed consent.

        Exclusion Criteria:

          -  Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism
             correctly treated and controlled).

          -  Pregnancy or pregnancy planning.

          -  Diabetes mellitus type 2.

          -  Hyperuricemia (uric acid ≥7 mg / dl at the time of inclusion or current treatment With
             allopurinol).

          -  Absence of collaboration (informed consent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria Soledad Ruiz de Adana, MD PhD</last_name>
    <phone>+34 629221089</phone>
    <email>solruizdeadana@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regional University Hospital of Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Soledad Ruiz de Adana, MD PhD</last_name>
      <phone>+34 629221089</phone>
      <email>solruizdeadana@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001 Jan;86(1):450-3.</citation>
    <PMID>11232040</PMID>
  </reference>
  <reference>
    <citation>Arufe MC, Lu M, Lin RY. Differentiation of murine embryonic stem cells to thyrocytes requires insulin and insulin-like growth factor-1. Biochem Biophys Res Commun. 2009 Apr 3;381(2):264-70. doi: 10.1016/j.bbrc.2009.02.035. Epub 2009 Feb 14.</citation>
    <PMID>19232325</PMID>
  </reference>
  <reference>
    <citation>Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev. 2009 Jan;89(1):27-71. doi: 10.1152/physrev.00014.2008. Review.</citation>
    <PMID>19126754</PMID>
  </reference>
  <reference>
    <citation>Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991 Apr;40(4):405-12. Review.</citation>
    <PMID>2010041</PMID>
  </reference>
  <reference>
    <citation>Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999 Jan;48(1):1-9. Review.</citation>
    <PMID>9892215</PMID>
  </reference>
  <reference>
    <citation>Berg TJ, Nourooz-Zadeh J, Wolff SP, Tritschler HJ, Bangstad HJ, Hanssen KF. Hydroperoxides in plasma are reduced by intensified insulin treatment. A randomized controlled study of IDDM patients with microalbuminuria. Diabetes Care. 1998 Aug;21(8):1295-300.</citation>
    <PMID>9702436</PMID>
  </reference>
  <reference>
    <citation>Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, Ahmann AJ. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017 Apr;40(4):554-560. doi: 10.2337/dc16-0684. Epub 2017 Jan 23.</citation>
    <PMID>28115474</PMID>
  </reference>
  <reference>
    <citation>Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17.</citation>
    <PMID>23710902</PMID>
  </reference>
  <reference>
    <citation>Bravi MC, Armiento A, Laurenti O, Cassone-Faldetta M, De Luca O, Moretti A, De Mattia G. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism. 2006 May;55(5):691-5.</citation>
    <PMID>16631447</PMID>
  </reference>
  <reference>
    <citation>Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25.</citation>
    <PMID>15919781</PMID>
  </reference>
  <reference>
    <citation>Ceolotto G, Bevilacqua M, Papparella I, Baritono E, Franco L, Corvaja C, Mazzoni M, Semplicini A, Avogaro A. Insulin generates free radicals by an NAD(P)H, phosphatidylinositol 3'-kinase-dependent mechanism in human skin fibroblasts ex vivo. Diabetes. 2004 May;53(5):1344-51.</citation>
    <PMID>15111505</PMID>
  </reference>
  <reference>
    <citation>Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S15-9. doi: 10.1097/01.hjr.0000368193.24732.66. Review.</citation>
    <PMID>20489415</PMID>
  </reference>
  <reference>
    <citation>Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabet Med. 2010 Aug;27(8):911-7. doi: 10.1111/j.1464-5491.2009.02928.x.</citation>
    <PMID>20653749</PMID>
  </reference>
  <reference>
    <citation>Ceriello A, Ihnat M. Oxidative stress is, convincingly, the mediator of the dangerous effects of glucose variability. Diabet Med. 2010 Aug;27(8):968. doi: 10.1111/j.1464-5491.2010.02931.x.</citation>
    <PMID>20653758</PMID>
  </reference>
  <reference>
    <citation>Ceriello A, Novials A, Ortega E, Canivell S, La Sala L, Pujadas G, Esposito K, Giugliano D, Genovese S. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care. 2013 Aug;36(8):2346-50. doi: 10.2337/dc12-2469. Epub 2013 Apr 5.</citation>
    <PMID>23564922</PMID>
  </reference>
  <reference>
    <citation>Costacou T, Evans RW, Schafer GL, Orchard TJ. Oxidative stress and response in relation to coronary artery disease in type 1 diabetes. Diabetes Care. 2013 Nov;36(11):3503-9. doi: 10.2337/dc12-2378. Epub 2013 Aug 6.</citation>
    <PMID>23920084</PMID>
  </reference>
  <reference>
    <citation>Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, Orchard TJ. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications. 2005 Jul-Aug;19(4):183-93.</citation>
    <PMID>15993351</PMID>
  </reference>
  <reference>
    <citation>Chang L, Chiang SH, Saltiel AR. Insulin signaling and the regulation of glucose transport. Mol Med. 2004 Jul-Dec;10(7-12):65-71. Review.</citation>
    <PMID>16307172</PMID>
  </reference>
  <reference>
    <citation>Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001 Jul;86(7):3257-65.</citation>
    <PMID>11443198</PMID>
  </reference>
  <reference>
    <citation>Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Effect of hyperglycemia and insulin in acute coronary syndromes. Am J Cardiol. 2007 Jun 4;99(11A):12H-18H. Review.</citation>
    <PMID>17665748</PMID>
  </reference>
  <reference>
    <citation>Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S14-20. doi: 10.1016/j.jacc.2008.10.038. Review.</citation>
    <PMID>19179212</PMID>
  </reference>
  <reference>
    <citation>Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008 Aug;10(4):273-7. doi: 10.1089/dia.2008.0282.</citation>
    <PMID>18715200</PMID>
  </reference>
  <reference>
    <citation>Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988 Jul-Aug;11(7):567-73.</citation>
    <PMID>2904881</PMID>
  </reference>
  <reference>
    <citation>Domínguez C, Ruiz E, Gussinye M, Carrascosa A. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care. 1998 Oct;21(10):1736-42.</citation>
    <PMID>9773740</PMID>
  </reference>
  <reference>
    <citation>Fawcett J, Tsui BT, Kruer MC, Duckworth WC. Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Metabolism. 2004 Aug;53(8):1037-44.</citation>
    <PMID>15281015</PMID>
  </reference>
  <reference>
    <citation>Francescato MP, Stel G, Geat M, Cauci S. Oxidative stress in patients with type 1 diabetes mellitus: is it affected by a single bout of prolonged exercise? PLoS One. 2014 Jun 6;9(6):e99062. doi: 10.1371/journal.pone.0099062. eCollection 2014.</citation>
    <PMID>24905823</PMID>
  </reference>
  <reference>
    <citation>Franklin VL, Khan F, Kennedy G, Belch JJ, Greene SA. Intensive insulin therapy improves endothelial function and microvascular reactivity in young people with type 1 diabetes. Diabetologia. 2008 Feb;51(2):353-60. Epub 2007 Nov 27.</citation>
    <PMID>18040663</PMID>
  </reference>
  <reference>
    <citation>García-Escobar E, Rodríguez-Pacheco F, Haro-Mora JJ, Gomez-Zumaquero JM, Rubio-Martín E, Gutierrez-Repiso C, Soriguer F, Rojo-Martínez G. Effect of insulin analogues on 3t3-l1 adipogenesis and lipolysis. Eur J Clin Invest. 2011 Sep;41(9):979-86. doi: 10.1111/j.1365-2362.2011.02492.x. Epub 2011 Mar 2.</citation>
    <PMID>21366560</PMID>
  </reference>
  <reference>
    <citation>Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545. Review.</citation>
    <PMID>21030723</PMID>
  </reference>
  <reference>
    <citation>Goldman J, White JR Jr. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus. Ann Pharmacother. 2015 Oct;49(10):1153-61. doi: 10.1177/1060028015597915. Epub 2015 Aug 3. Review.</citation>
    <PMID>26238470</PMID>
  </reference>
  <reference>
    <citation>Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000 May;23(5):644-9.</citation>
    <PMID>10834424</PMID>
  </reference>
  <reference>
    <citation>Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.</citation>
    <PMID>22594461</PMID>
  </reference>
  <reference>
    <citation>Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015 Dec;38(12):2217-25. doi: 10.2337/dc15-0249. Epub 2015 Jun 17.</citation>
    <PMID>26084341</PMID>
  </reference>
  <reference>
    <citation>Hoeldtke RD, Bryner KD, Hoeldtke ME, Christie I, Ganser G, Hobbs G, Riggs J. Sympathetic sudomotor disturbance in early type 1 diabetes mellitus is linked to lipid peroxidation. Metabolism. 2006 Nov;55(11):1524-31.</citation>
    <PMID>17046556</PMID>
  </reference>
  <reference>
    <citation>Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003 Jul;26(7):2027-31.</citation>
    <PMID>12832307</PMID>
  </reference>
  <reference>
    <citation>Liu HY, Cao SY, Hong T, Han J, Liu Z, Cao W. Insulin is a stronger inducer of insulin resistance than hyperglycemia in mice with type 1 diabetes mellitus (T1DM). J Biol Chem. 2009 Oct 2;284(40):27090-100. doi: 10.1074/jbc.M109.016675. Epub 2009 Aug 4.</citation>
    <PMID>19654321</PMID>
  </reference>
  <reference>
    <citation>Højlund K, Poulsen M, Staehr P, Brusgaard K, Beck-Nielsen H. Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes. Eur J Clin Invest. 2002 Dec;32(12):918-23.</citation>
    <PMID>12534451</PMID>
  </reference>
  <reference>
    <citation>Järvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, Lehtimäki T, Rönnemaa T, Viikari J, Raitakari OT. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation. 2004 Apr 13;109(14):1750-5. Epub 2004 Mar 15.</citation>
    <PMID>15023875</PMID>
  </reference>
  <reference>
    <citation>Kalra S, Baruah MP, Niazi AK. Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):18-23. Review.</citation>
    <PMID>22280221</PMID>
  </reference>
  <reference>
    <citation>Korytkowski MT, Salata RJ, Koerbel GL, Selzer F, Karslioglu E, Idriss AM, Lee KK, Moser AJ, Toledo FG. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009 Apr;32(4):594-6. doi: 10.2337/dc08-1436.</citation>
    <PMID>19336639</PMID>
  </reference>
  <reference>
    <citation>Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000 Jun;49(6):999-1005.</citation>
    <PMID>10866053</PMID>
  </reference>
  <reference>
    <citation>Laaksonen DE, Atalay M, Niskanen L, Uusitupa M, Hänninen O, Sen CK. Increased resting and exercise-induced oxidative stress in young IDDM men. Diabetes Care. 1996 Jun;19(6):569-74.</citation>
    <PMID>8725853</PMID>
  </reference>
  <reference>
    <citation>Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142-8.</citation>
    <PMID>11118018</PMID>
  </reference>
  <reference>
    <citation>Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009 Jan;11(1):45-52. doi: 10.1111/j.1463-1326.2008.00915.x. Epub 2008 Jul 17.</citation>
    <PMID>18643839</PMID>
  </reference>
  <reference>
    <citation>Mäkimattila S, Virkamäki A, Malmström R, Utriainen T, Yki-Jarvinen H. Insulin resistance in type I diabetes mellitus: a major role for reduced glucose extraction. J Clin Endocrinol Metab. 1996 Feb;81(2):707-12.</citation>
    <PMID>8636292</PMID>
  </reference>
  <reference>
    <citation>Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009 Jan;11(1):53-9. doi: 10.1111/j.1463-1326.2008.00934.x. Epub 2008 Jul 29. Review.</citation>
    <PMID>18671795</PMID>
  </reference>
  <reference>
    <citation>Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda G, Santini SA. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care. 2002 Feb;25(2):370-5.</citation>
    <PMID>11815512</PMID>
  </reference>
  <reference>
    <citation>Matsuhisa M, Koyama M, Cheng X, Sumi M, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension). Diabetes Res Clin Pract. 2016 Dec;122:133-140. doi: 10.1016/j.diabres.2016.10.002. Epub 2016 Oct 13.</citation>
    <PMID>27835765</PMID>
  </reference>
  <reference>
    <citation>Delmastro MM, Piganelli JD. Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol. 2011;2011:593863. doi: 10.1155/2011/593863. Epub 2011 May 18.</citation>
    <PMID>21647409</PMID>
  </reference>
  <reference>
    <citation>Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010 Mar;53(3):562-71. doi: 10.1007/s00125-009-1574-6. Epub 2009 Nov 5.</citation>
    <PMID>19890623</PMID>
  </reference>
  <reference>
    <citation>Monnier L, Hanefeld M, Schnell O, Colette C, Owens D. Insulin and atherosclerosis: how are they related? Diabetes Metab. 2013 Apr;39(2):111-7. doi: 10.1016/j.diabet.2013.02.001. Epub 2013 Mar 15. Review.</citation>
    <PMID>23507269</PMID>
  </reference>
  <reference>
    <citation>Muchmore DB, Heinemann L, Tamborlane W, Wu XW, Fleming A. Assessing rates of hypoglycemia as an end point in clinical trials. Diabetes Care. 2015 Oct;38(10):e160-1. doi: 10.2337/dc15-0808. Epub 2015 Aug 17.</citation>
    <PMID>26283738</PMID>
  </reference>
  <reference>
    <citation>Muretta JM, Mastick CC. How insulin regulates glucose transport in adipocytes. Vitam Horm. 2009;80:245-86. doi: 10.1016/S0083-6729(08)00610-9. Review.</citation>
    <PMID>19251041</PMID>
  </reference>
  <reference>
    <citation>Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol. 2011 Aug 2;108(3 Suppl):42B-51B. doi: 10.1016/j.amjcard.2011.03.015. Review.</citation>
    <PMID>21802580</PMID>
  </reference>
  <reference>
    <citation>ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.</citation>
    <PMID>22686416</PMID>
  </reference>
  <reference>
    <citation>Østerberg O, Erichsen L, Ingwersen SH, Plum A, Poulsen HE, Vicini P. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):221-35.</citation>
    <PMID>14571692</PMID>
  </reference>
  <reference>
    <citation>Scheen AJ. New therapeutic approaches in type 2 diabetes. Acta Clin Belg. 2008 Nov-Dec;63(6):402-7. Review.</citation>
    <PMID>19170358</PMID>
  </reference>
  <reference>
    <citation>Razavi Nematollahi L, Kitabchi AE, Stentz FB, Wan JY, Larijani BA, Tehrani MM, Gozashti MH, Omidfar K, Taheri E. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2009 Apr;58(4):443-8. doi: 10.1016/j.metabol.2008.10.018. Erratum in: Metabolism. 2009 Jul;58(7):1046. Kitabchi, Abbas Eghbal [corrected to Kitabchi, Abbas E].</citation>
    <PMID>19303962</PMID>
  </reference>
  <reference>
    <citation>Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005 Apr;28(4):950-5.</citation>
    <PMID>15793205</PMID>
  </reference>
  <reference>
    <citation>Sanders EJ, Harvey S. Peptide hormones as developmental growth and differentiation factors. Dev Dyn. 2008 Jun;237(6):1537-52. doi: 10.1002/dvdy.21573. Review.</citation>
    <PMID>18498096</PMID>
  </reference>
  <reference>
    <citation>Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013 May;36(5):1384-95. doi: 10.2337/dc12-2480. Epub 2013 Apr 15.</citation>
    <PMID>23589542</PMID>
  </reference>
  <reference>
    <citation>Singh P, Jain A, Kaur G. Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem. 2004 May;260(1-2):153-9.</citation>
    <PMID>15228097</PMID>
  </reference>
  <reference>
    <citation>Somwar R, Sweeney G, Ramlal T, Klip A. Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther. 1998 Jan-Feb;20(1):125-40.</citation>
    <PMID>9522110</PMID>
  </reference>
  <reference>
    <citation>Steensgaard DB, Schluckebier G, Strauss HM, Norrman M, Thomsen JK, Friderichsen AV, Havelund S, Jonassen I. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013 Jan 15;52(2):295-309. doi: 10.1021/bi3008609. Epub 2013 Jan 3.</citation>
    <PMID>23256685</PMID>
  </reference>
  <reference>
    <citation>Varvarovská J, Racek J, Stetina R, Sýkora J, Pomahacová R, Rusavý Z, Lacigová S, Trefil L, Siala K, Stozický F. Aspects of oxidative stress in children with type 1 diabetes mellitus. Biomed Pharmacother. 2004 Dec;58(10):539-45.</citation>
    <PMID>15589060</PMID>
  </reference>
  <reference>
    <citation>Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.</citation>
    <PMID>25081590</PMID>
  </reference>
  <reference>
    <citation>Wang J, Alexanian A, Ying R, Kizhakekuttu TJ, Dharmashankar K, Vasquez-Vivar J, Gutterman DD, Widlansky ME. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):712-20. doi: 10.1161/ATVBAHA.111.227389. Epub 2011 Dec 29.</citation>
    <PMID>22207730</PMID>
  </reference>
  <reference>
    <citation>Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987 Jul 1;245(1):243-50.</citation>
    <PMID>3117042</PMID>
  </reference>
  <reference>
    <citation>Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):353-63. doi: 10.1002/dmrr.865. Review.</citation>
    <PMID>18461635</PMID>
  </reference>
  <reference>
    <citation>Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006 Nov;8(6):611-20. Review.</citation>
    <PMID>17026485</PMID>
  </reference>
  <reference>
    <citation>Ziegler D, Buchholz S, Sohr C, Nourooz-Zadeh J, Roden M. Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients. Acta Diabetol. 2015 Feb;52(1):65-72. doi: 10.1007/s00592-014-0601-3. Epub 2014 Jun 5.</citation>
    <PMID>24898524</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2017</study_first_submitted>
  <study_first_submitted_qc>October 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</investigator_affiliation>
    <investigator_full_name>Virginia Morillas</investigator_full_name>
    <investigator_title>Maria Soledad Ruiz de Adana</investigator_title>
  </responsible_party>
  <keyword>Oxidation</keyword>
  <keyword>Insulin analogues</keyword>
  <keyword>Type 1 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

